The Changing Landscape of Global Biopharmaceutical Leadership, 2004–2024
- 1National Pharmaceutical Council, 1717 Pennsylvania Ave NW #800, Washington, DC 20006 USA
Abstract
For several decades, the United States (U.S.) has been the leader in biopharmaceutical advancements. Recently, the U.S. has increased government interventions to limit prices for patent-protected medicines. While it is unclear whether ongoing efforts to implement international reference pricing in the U.S. could have similar effects, descriptive measures of global biopharmaceutical market dynamics can help benchmark future assessments. In this analysis, we analyzed trends in the geographic distribution of select measures of biopharmaceutical leadership from 2004 through 2024. Using the PharmaProjects database from Citeline, we found that 43.1% of first launches of small-molecule and biologic drugs occurred in the U.S., 15.3% occurred in Europe, and 9.9% occurred in China. Over this time, the share of drugs launched first in the U.S. went from 45.9 to 37.8%, the share of drugs launched first in Europe fell from 26.7 to 8.5%, while this share in China grew from 3.3 to 28.7%. The share of first-launched therapeutics developed by U.S.-headquartered companies and by companies based in Europe declined while the share developed by companies based in China increased. Though additional research is needed on the measurement of biopharmaceutical leadership, and impacts of government intervention, this descriptive study suggests that over several decades, there has been a strong decline in European measures of leadership. At the same time, China is becoming increasingly important in the global biopharmaceutical space. This analysis supports the view that the U.S remains a leader, and offers a benchmark and context for future evaluations that consider potential unintended consequences of ongoing proposals to increase government intervention in the prices of patent-protected medicines.
Related
- Gradient Descent on Two ReLU Neurons: Global Landscape and Bifurcation Dynamics
- The quantitative non-unique-product landscape at the global minimum: the Nielsen-Soelberg groups
- Statistical Leadership of What? Statistics After AI
- University Research and Leadership in the Age of AI: Mobilizing Intellectual Capacity and Building the Infrastructure for Discovery
- Least energy sign-changing solutions for asymptotically cubic Kirchhoff equations on locally finite graphs
BibTeX
@article{feyman2026changing,
title = {{The Changing Landscape of Global Biopharmaceutical Leadership, 2004–2024}},
author = {Yevgeniy Feyman and John M. O’Brien and Jonathan D. Campbell},
journal = {Therapeutic Innovation \& Regulatory Science},
year = {2026},
month = aug,
doi = {10.1007/s43441-026-01031-w},
url = {https://doi.org/10.1007/s43441-026-01031-w},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The Changing Landscape of Global Biopharmaceutical Leadership, 2004–2024
AU - Yevgeniy Feyman
AU - John M. O’Brien
AU - Jonathan D. Campbell
PY - 2026
DA - 2026/08/07
JO - Therapeutic Innovation & Regulatory Science
DO - 10.1007/s43441-026-01031-w
UR - https://doi.org/10.1007/s43441-026-01031-w
AB - For several decades, the United States (U.S.) has been the leader in biopharmaceutical advancements. Recently, the U.S. has increased government interventions to limit prices for patent-protected medicines. While it is unclear whether ongoing efforts to implement international reference pricing in the U.S. could have similar effects, descriptive measures of global biopharmaceutical market dynamics can help benchmark future assessments. In this analysis, we analyzed trends in the geographic distribution of select measures of biopharmaceutical leadership from 2004 through 2024. Using the PharmaProjects database from Citeline, we found that 43.1% of first launches of small-molecule and biologic drugs occurred in the U.S., 15.3% occurred in Europe, and 9.9% occurred in China. Over this time, the share of drugs launched first in the U.S. went from 45.9 to 37.8%, the share of drugs launched first in Europe fell from 26.7 to 8.5%, while this share in China grew from 3.3 to 28.7%. The share of first-launched therapeutics developed by U.S.-headquartered companies and by companies based in Europe declined while the share developed by companies based in China increased. Though additional research is needed on the measurement of biopharmaceutical leadership, and impacts of government intervention, this descriptive study suggests that over several decades, there has been a strong decline in European measures of leadership. At the same time, China is becoming increasingly important in the global biopharmaceutical space. This analysis supports the view that the U.S remains a leader, and offers a benchmark and context for future evaluations that consider potential unintended consequences of ongoing proposals to increase government intervention in the prices of patent-protected medicines.
SN - 2168-4790
SN - 2168-4804
ER -